CSL Behring

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.

Source: https://www.cslbehring.com/

albutrepenonacog alfaIdelvion

recombinant coagulation factor IX

Idelvion (albutrepenonacog alfa) is a long-acting recombinant factor IX product from CSL Behring for haemophilia B. Fused to albumin, it replaces the clotting factor that patients lack, preventing and treating bleeding episodes and reducing the need for frequent infusions.

In haemophilia B the body cannot make enough functional factor IX, a protein needed for blood to clot, so injuries lead to prolonged or spontaneous bl

1 medicine explained